The LOGEX IMID Observatory

A retrospective, longitudinal, multi-country, harmonised and clinically validated RWE platform that supports improved standards of care for immune-mediated inflammatory diseases (IMIDs).

Retrospective | Longitudinal | Multi-country | Harmonised | Clinically validated

THREE THERAPEUTIC FOCUS AREAS

Coverage of three therapeutic areas that collectively encompass a broad spectrum of immune-mediated inflammatory diseases characterised by shared immune dysregulation.

Dermatology

IMIDs characterised by chronic inflammation of the skin and related tissues.

- Psoriasis
- Hidradenitis suppurativa
- Atopic dermatitis

Rheumatology

IMIDs encompassing inflammatory arthritis, spondyloarthropathies, and systemic autoimmune disorders.

- Rheumatoid arthritis
- Psoriatic arthritis
- Axial spondyloarthritis

Gastroenterology

IMIDs characterised by chronic inflammation of the gastrointestinal tract and associated digestive organs.

- Crohn's disease
- Ulcerative colitis
- Eosinophilic oesophagitis

IMIDS EVOLVE ACROSS SPECIALTIES

IMIDs share underlying immune dysregulation and inflammatory pathways. Over time, patients may develop additional IMIDs affecting different organ systems, creating complex cross-specialty care pathways. The Observatory captures this evolution through longitudinal and integrated real-world data.

Day 1 — Year 2+

DERMATOLOGY (Specialty) → DERMATOLOGY + RHEUMATOLOGY (Specialty)

5 Insight domains to generate actionable insights

Integrated longitudinal and cross-specialty data generate actionable insights across the IMID patient journey to inform care.

Patient baseline & disease history

- Demographics
- Coexisting IMIDs
- Comorbidities
- Clinical characteristics

Healthcare resource utilisation

- Hospitalisations
- ICU, ER, specialist visits
- Surgeries
- Procedures
- Costs

Treatment patterns & use

- Sequencing
- Switching
- Duration/survival
- Time-to-next-treatment
- Dosing

Diagnosis & clinical monitoring

- Disease activity scores (evolution)
- Disease progression proxies
- Biomarker assessment

Treatment initiation

- Prior therapy exposure
- Initiation patterns
- Biosimilar uptake
- Advanced systemic therapy-naïve vs experienced

Resource utilisation & monthly costs

Comparing resource-use and monthly cost profiles across treatment groups.

Treatment sequencing by medication class

Illustrative Sankey of treatment sequencing across therapeutic classes over time.



One patient. Multiple data sources.

A growing and holistic longitudinal view of the clinical journey.

One European framework

37,000+ IMID patients across multiple countries

- Spain
- Netherlands
- United Kingdom
- + more

Built in collaboration with participating hospitals

A longitudinal and continuously growing cohort



Zoom in: the integrated patient's journey

Patient 18,452
Pseudonymised ID

Past — Diagnosis — Today — Future

Up to 5-year look-back — Ongoing follow-up

- Medication
- Diagnosis
- Lab data
- HCRU (Healthcare Resource Utilisation)
- Specialty: Dermatology — Rheumatology

Longitudinal data integration across specialties capturing disease evolution and care pathways.

Enabling real-world insights to improve outcomes for people living with IMID.

Real patients | Real-world data | Real impact

FROM EVIDENCE TO ACTION

Integrated longitudinal data generate actionable insights that support continuous learning and informed decision making across IMID care pathways.

1. **Inform earlier identification:** Monitor healthcare activity patterns preceding diagnosis to inform clinical review of specific patient subsets.
2. **Support treatment optimisation:** Evaluate treatment dosing, switching, sequencing, survival and biosimilar and steroid utilisation in routine clinical practice to inform treatment strategies.
3. **Inform disease monitoring practices:** Assess biomarker monitoring, disease activity assessment and follow-up patterns to understand disease control and treatment response in routine clinical practice.
4. **Understand disease burden and progression:** Quantify the clinical burden of IMIDs, including disease evolution, progression, healthcare utilisation and long-term outcomes across the patient journey.
5. **Support multidisciplinary IMID management:** investigate cross-specialty care pathways, coexisting IMIDs and their impact on treatment patterns, healthcare utilisation and patient outcomes to support coordinated patient management.

A continuously growing evidence base

Patients and data grow over time — Real patients — Real-world data — Real impact

2019 — 2023 — 2025 — Now — Ongoing

LOGEX